Jérôme Chetritt
YOU?
Author Swipe
View article: Real-world analysis of HER2-ultralow in HR+/HER2– metastatic breast cancer: prevalence and first-line chemotherapy outcomes
Real-world analysis of HER2-ultralow in HR+/HER2– metastatic breast cancer: prevalence and first-line chemotherapy outcomes Open
Background: HER2-ultralow is an emerging subgroup of metastatic breast cancer (mBC). However, despite an increasing interest, limited data exist on its prevalence and outcomes, especially among patients receiving standard first-line chemot…
View article: The inhibitory receptor CD94/NKG2A on CD8+ tumor-infiltrating lymphocytes in colorectal cancer: a promising new druggable immune checkpoint in the context of HLAE/β2m overexpression
The inhibitory receptor CD94/NKG2A on CD8+ tumor-infiltrating lymphocytes in colorectal cancer: a promising new druggable immune checkpoint in the context of HLAE/β2m overexpression Open
View article: The density of Tbet+ tumor-infiltrating T lymphocytes reflects an effective and druggable preexisting adaptive antitumor immune response in colorectal cancer, irrespective of the microsatellite status
The density of Tbet+ tumor-infiltrating T lymphocytes reflects an effective and druggable preexisting adaptive antitumor immune response in colorectal cancer, irrespective of the microsatellite status Open
Purpose: The recent success of anti-PD1 antibody in metastatic colorectal cancer (CRC) patients with microsatellite instability (MSI), known to be associated with an upregulated Th1/Tc1 gene signature, provides new promising therape…
View article: uPA/PAI-1, Oncotype DX™, MammaPrint®. Valeurs pronostique et prédictive pour une utilité clinique dans la prise en charge du cancer du sein
uPA/PAI-1, Oncotype DX™, MammaPrint®. Valeurs pronostique et prédictive pour une utilité clinique dans la prise en charge du cancer du sein Open